OS Therapies Inc. Announces Completion of Last Patient Visit in OST-504 Phase 1b Prostate Cancer Clinical Trial; Results Expected Q4 2025
Reuters
Sep 12, 2025
<a href="https://laohu8.com/S/OSTX">OS Therapies</a> Inc. Announces Completion of Last Patient Visit in OST-504 Phase 1b Prostate Cancer Clinical Trial; Results Expected Q4 2025
OS Therapies Inc., a clinical-stage biotechnology company specializing in cancer immunotherapy and antibody drug conjugates, announced the completion of patient visits for their OST-504 Phase 1b clinical trial. The trial, which involved seven patients with biochemically recurrent prostate cancer, has concluded all patient interactions, and the company plans to release the clinical data in the fourth quarter of 2025. Additionally, OS Therapies will present updated two-year overall survival data from its Phase 2b clinical trial of OST-HER2, focused on preventing recurrent pulmonary metastatic osteosarcoma, on October 10, 2025. These developments are part of the company's ongoing efforts to address significant unmet medical needs in cancer treatment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 266139) on September 12, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.